Here, we demonstrated that the selective induction of early IR, without hyperglycemia as a confounding factor, worsens stroke recovery and that the pharmacological treatment of IR with the PPARγ agonist Rosiglitazone counteracts this effect, strongly supporting IR as a causative factor at the basis of impaired stroke recovery. Here, PPARG is linked to Hyperglycemia.